|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:activities
|
depletes C D52-expressing lymphocytes
|
|
gptkbp:affects
|
immunosuppression
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
gptkb:Lemtrada
|
|
gptkbp:clinical_trial
|
Phase III
disease-modifying therapy
CAMM S223
CARE-MSI
CARE-MSII
|
|
gptkbp:contraindication
|
hypersensitivity to alemtuzumab
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
5 days in the first year, 3 days in the second year
|
|
gptkbp:events
|
regular monitoring for autoimmune diseases
|
|
gptkbp:formulation
|
sterile solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lemtrada
|
|
gptkbp:indication
|
gptkb:relapsing_forms_of_multiple_sclerosis
|
|
gptkbp:ingredients
|
gptkb:alemtuzumab
|
|
gptkbp:is_monitored_by
|
blood counts
|
|
gptkbp:is_used_for
|
gptkb:psychologist
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:manufacturer
|
gptkb:Sanofi_Genzyme
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
long half-life
|
|
gptkbp:population
|
adults
|
|
gptkbp:price
|
high
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Avonex
gptkb:Tysabri
gptkb:Rebif
gptkb:Ocrevus
gptkb:Vumerity
gptkb:Zinbryta
gptkb:Campath
gptkb:Copaxone
gptkb:Gilenya
gptkb:Mayzent
|
|
gptkbp:scholarships
|
available through manufacturer programs
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
rash
infections
thyroid disorders
infusion reactions
autoimmune conditions
|
|
gptkbp:storage
|
refrigerated
|